A team of surgeons at Duke University Hospital has successfully implanted a new-generation commercially-available total artificial heart, the first of such achievement in the USA.&nbsp; The patient was a 39-year-old man who suffered a heart failure.The Aeson artificial heart was developed by French company CARMAT, who obtained FDA approval in the USA to enroll patients with end-stage biventricular heart failure for a study.&nbsp; The artificial heart uses biological valves derived from bovine tissues and operates on an external power supply.CARMAT’s artificial heart is designed to provide a temporary device for patients waiting for heart transplant surgeries. “Because of the shortages of donor hearts, many patients die while waiting for a heart transplant,” <a href="https://medschool.duke.edu/about-us/news-and-communications/med-school-blog/new-generation-artificial-heart-implanted-patient-duke-%E2%80%93-first-us" class="on">said transplant surgeon Jacob Schroder</a>, who led the implant procedure. “We are hopeful for new options to help these patients, many like [the patient] who have devastating disease and cannot otherwise be considered for a transplant.”#heart #surgery #transplant #hearttransplant #transplantsurgery #artificialheart #CARMAT